Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000730926 | SCV000858693 | uncertain significance | not provided | 2017-12-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001222490 | SCV001394589 | uncertain significance | Bethlem myopathy 1A | 2022-03-18 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL6A2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 595396). This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 838 of the COL6A2 protein (p.Leu838Pro). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with COL6A2-related conditions. |